Lercanidipin Stada (Lercanidipine Hydrochloride)

Lercanidipine is used to treat conditions within the hypertension disease family by relaxing vascular smooth muscle and lowering arterial pressure.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Isolated systolic hypertension: improves pulse pressure in older patients.
• Hypertension in the elderly: provides effective blood pressure control with once‑daily dosing.

• Lercanidipine selectively blocks L‑type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to arterial vasodilation, decreased peripheral vascular resistance, and ultimately a reduction in systemic blood pressure without significant negative inotropic effects on the heart.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity, often occurring early in therapy.
• Flushing: warm sensation and reddening of the skin, usually transient.
• Peripheral edema: swelling of the ankles or lower legs due to vasodilation.
• Dizziness or light‑headedness, especially when standing quickly.
• Tachycardia: increased heart rate as a reflex response.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: assess baseline and periodic readings to avoid excessive hypotension.
• Hepatic impairment: use with caution and consider dose adjustment in patients with liver disease.
• Elderly patients: start at the lowest effective dose due to increased sensitivity.
• Concomitant antihypertensives: watch for additive blood‑pressure‑lowering effects.
• Discontinuation: avoid abrupt cessation to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Grapefruit juice: can markedly raise drug levels and risk of hypotension.
• Other potent antihypertensives: additive blood‑pressure‑lowering effect leading to severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Beta‑blockers: may require careful titration to avoid excessive heart‑rate reduction.
• Diuretics: monitor electrolytes and blood pressure for synergistic effects.